The Experts below are selected from a list of 2385 Experts worldwide ranked by ideXlab platform
Peter M. Schlag - One of the best experts on this subject based on the ideXlab platform.
-
Preclinical study on combined chemo- and Nonviral Gene Therapy for sensitization of melanoma using a human TNF-alpha expressing MIDGE DNA vector
Molecular oncology, 2014Co-Authors: Dennis Kobelt, Iduna Fichtner, Peter M. Schlag, Jutta Aumann, Manuel Schmidt, Burghardt Wittig, Diana Behrens, Margit Lemm, Greta Freundt, Wolfgang WaltherAbstract:Nonviral Gene Therapy represents a realistic option for clinical application in cancer treatment. This preclinical study demonstrates the advantage of using the small-size MIDGE �
-
Low-volume jet injection for efficient Nonviral in vivo Gene transfer
Molecular Biotechnology, 2004Co-Authors: Wolfgang Walther, Ulrike Stein, Iduna Fichtner, Peter M. SchlagAbstract:The transfer of naked deoxyribonucleic acid (DNA) represents an alternative to viral and liposomal Gene transfer technologies for Gene Therapy applications. Various procedures are employed to deliver naked DNA into the desired cells or tissues in vitro and in vivo, such as by simple needle injection, particle bombardment, in vivo electroporation or jet injection. Among the various Nonviral Gene delivery technologies jet injection is gaining increasing acceptance because it allows Gene transfer into different tissues with deeper penetration of the applied naked DNA. The versatile hand-held Swiss jet injector uses pressurized air to force small volumes of 3 to 10 µL of naked DNA into targeted tissues. The β-galactosidase ( LacZ ) reporter Gene construct and tumor necrosis factor α Gene-expressing vectors were successfully jet injected at a pressure of 3.0 bar into xenotransplanted human tumor models of colon carcinoma. Qualitative and quantitative expression analysis of jet injected tumor tissues revealed the efficient expression of these Genes in the tumors. Using this Swiss jet-injector prototype repeated jet injections of low volumes (3–10 µL) into one target tissue can easily be performed. The key parameters of in vivo jet injection such as jet injection volume, pressure, jet penetration into the tumor tissue, DNA stability have been defined for optimized Nonviral Gene Therapy. These studies demonstrate the applicability of the jet injection technology for the efficient and simultaneous in vivo Gene transfer of two different plasmid DNAs into tumors. It can be employed for Nonviral Gene Therapy of cancer using minimal amounts of naked DNA.
-
Stability analysis for long-term storage of naked DNA: impact on Nonviral in vivo Gene transfer.
Analytical biochemistry, 2003Co-Authors: Wolfgang Walther, Carsten Voss, Ulrike Stein, M. Schleef, Torsten Schmidt, Peter M. SchlagAbstract:The transfer of naked DNA is gaining growing acceptance for Nonviral Gene Therapy. Integrity and stability of the DNA used in Nonviral Gene Therapy is known to be decisive for efficacy of Gene transfer and transGene expression. Thus, preclinical and clinical studies require the safe storage of DNA preparations to ensure defined quality and conformation. To evaluate the influence of potentially destructive processes on plasmid DNA associated with long-term storage, capillary gel electrophoresis (CGE) analysis of the LacZ-expressing pCMVbeta plasmid over a period of 13 months was performed. The CGE analysis revealed that stable storage conditions at -80 degrees C prevent an increase in open circular (oc) plasmid, preserving the covalently closed circular (ccc) form, which is sought for efficient Gene transfer. By contrast, long-term storage of plasmid DNA at 4 degrees C leads to the rapid decline of the ccc form and the increase of oc and linear DNA molecules. The use of naked DNA stored for 1, 2, or 13 months at -80 degrees C showed similar in vivo transfer efficiencies by jet-injection. Therefore, analysis of plasmids by CGE allows the reliable determination of integrity and distribution of the topology of the DNA by quantitative means.
-
Intratumoral low-volume jet-injection for efficient Nonviral Gene transfer
Molecular Biotechnology, 2002Co-Authors: Wolfgang Walther, Carsten Voss, Thomas Nellessen, Ulrike Stein, Iduna Fichtner, M. Schleef, Torsten Schmidt, Peter M. SchlagAbstract:Jet-injection has become an applicable technology among other established Nonviral delivery systems, such as particle bombardment or in vivo electroporation. The low-volume jet injector employed in this study uses compressed air to inject solutions of 1.5–10 µL containing naked DNA into the desired tissue. The novel design of this prototype makes multiple jet-injections possible. Therefore, repeated jet-injections into one target tissue can be performed easily. This jet-injector hand-held system was used for the direct in vivo Gene transfer of plasmid DNA into tumors to achieve efficient expression of reporter Genes (β-galactosidase, green fluorescent protein [GFP]) and of therapeutic Genes (TNF-α) in different tumor models. The study presented here revealed the key parameters of efficient in vivo jet-injection (jet-injection volume, pressure, jet penetration, DNA stability) to define the optimal conditions for a jet-injection-aided Nonviral Gene Therapy.
Wolfgang Walther - One of the best experts on this subject based on the ideXlab platform.
-
Preclinical study on combined chemo- and Nonviral Gene Therapy for sensitization of melanoma using a human TNF-alpha expressing MIDGE DNA vector
Molecular oncology, 2014Co-Authors: Dennis Kobelt, Iduna Fichtner, Peter M. Schlag, Jutta Aumann, Manuel Schmidt, Burghardt Wittig, Diana Behrens, Margit Lemm, Greta Freundt, Wolfgang WaltherAbstract:Nonviral Gene Therapy represents a realistic option for clinical application in cancer treatment. This preclinical study demonstrates the advantage of using the small-size MIDGE �
-
Low-volume jet injection for efficient Nonviral in vivo Gene transfer
Molecular Biotechnology, 2004Co-Authors: Wolfgang Walther, Ulrike Stein, Iduna Fichtner, Peter M. SchlagAbstract:The transfer of naked deoxyribonucleic acid (DNA) represents an alternative to viral and liposomal Gene transfer technologies for Gene Therapy applications. Various procedures are employed to deliver naked DNA into the desired cells or tissues in vitro and in vivo, such as by simple needle injection, particle bombardment, in vivo electroporation or jet injection. Among the various Nonviral Gene delivery technologies jet injection is gaining increasing acceptance because it allows Gene transfer into different tissues with deeper penetration of the applied naked DNA. The versatile hand-held Swiss jet injector uses pressurized air to force small volumes of 3 to 10 µL of naked DNA into targeted tissues. The β-galactosidase ( LacZ ) reporter Gene construct and tumor necrosis factor α Gene-expressing vectors were successfully jet injected at a pressure of 3.0 bar into xenotransplanted human tumor models of colon carcinoma. Qualitative and quantitative expression analysis of jet injected tumor tissues revealed the efficient expression of these Genes in the tumors. Using this Swiss jet-injector prototype repeated jet injections of low volumes (3–10 µL) into one target tissue can easily be performed. The key parameters of in vivo jet injection such as jet injection volume, pressure, jet penetration into the tumor tissue, DNA stability have been defined for optimized Nonviral Gene Therapy. These studies demonstrate the applicability of the jet injection technology for the efficient and simultaneous in vivo Gene transfer of two different plasmid DNAs into tumors. It can be employed for Nonviral Gene Therapy of cancer using minimal amounts of naked DNA.
-
Stability analysis for long-term storage of naked DNA: impact on Nonviral in vivo Gene transfer.
Analytical biochemistry, 2003Co-Authors: Wolfgang Walther, Carsten Voss, Ulrike Stein, M. Schleef, Torsten Schmidt, Peter M. SchlagAbstract:The transfer of naked DNA is gaining growing acceptance for Nonviral Gene Therapy. Integrity and stability of the DNA used in Nonviral Gene Therapy is known to be decisive for efficacy of Gene transfer and transGene expression. Thus, preclinical and clinical studies require the safe storage of DNA preparations to ensure defined quality and conformation. To evaluate the influence of potentially destructive processes on plasmid DNA associated with long-term storage, capillary gel electrophoresis (CGE) analysis of the LacZ-expressing pCMVbeta plasmid over a period of 13 months was performed. The CGE analysis revealed that stable storage conditions at -80 degrees C prevent an increase in open circular (oc) plasmid, preserving the covalently closed circular (ccc) form, which is sought for efficient Gene transfer. By contrast, long-term storage of plasmid DNA at 4 degrees C leads to the rapid decline of the ccc form and the increase of oc and linear DNA molecules. The use of naked DNA stored for 1, 2, or 13 months at -80 degrees C showed similar in vivo transfer efficiencies by jet-injection. Therefore, analysis of plasmids by CGE allows the reliable determination of integrity and distribution of the topology of the DNA by quantitative means.
-
Intratumoral low-volume jet-injection for efficient Nonviral Gene transfer
Molecular Biotechnology, 2002Co-Authors: Wolfgang Walther, Carsten Voss, Thomas Nellessen, Ulrike Stein, Iduna Fichtner, M. Schleef, Torsten Schmidt, Peter M. SchlagAbstract:Jet-injection has become an applicable technology among other established Nonviral delivery systems, such as particle bombardment or in vivo electroporation. The low-volume jet injector employed in this study uses compressed air to inject solutions of 1.5–10 µL containing naked DNA into the desired tissue. The novel design of this prototype makes multiple jet-injections possible. Therefore, repeated jet-injections into one target tissue can be performed easily. This jet-injector hand-held system was used for the direct in vivo Gene transfer of plasmid DNA into tumors to achieve efficient expression of reporter Genes (β-galactosidase, green fluorescent protein [GFP]) and of therapeutic Genes (TNF-α) in different tumor models. The study presented here revealed the key parameters of efficient in vivo jet-injection (jet-injection volume, pressure, jet penetration, DNA stability) to define the optimal conditions for a jet-injection-aided Nonviral Gene Therapy.
Gary A. Visner - One of the best experts on this subject based on the ideXlab platform.
-
Applications of Sleeping Beauty transposons for Nonviral Gene Therapy.
IUBMB life, 2007Co-Authors: Hanzhong Liu, Gary A. VisnerAbstract:Summary Virus-based Gene Therapy has advanced to clinical trials; however, this approach may result in serious adverse events including oncoGenesis and the possibility of triggering fatal immune responses. Nonviral Gene delivery approaches have a better safety profile, but their in vivo application has been largely limited in the past due to their inefficient delivery into cells and lack of stable chromosomal integration that is necessary for long-term therapeutic benefit. However, recent advances suggest that the use of Sleeping Beauty transposons, a novel integrating Nonviral vector system, are capable of achieving long-lasting therapeutic levels of transGene expression in preclinical settings. These observations and other ongoing relevant studies may unlock the therapeutic potential of Nonviral Gene Therapy for human diseases. IUBMB Life, 59: 374–379, 2007
Bradley S. Fletcher - One of the best experts on this subject based on the ideXlab platform.
-
Advancements in Non Viral Gene Therapy for Hemophilia
Journal of Genetic Syndromes & Gene Therapy, 2012Co-Authors: Bradley S. FletcherAbstract:Over the last 10-15 years, significant advances in vector design and delivery techniques have facilitated the development of Nonviral approaches for the treatment of hemophilia. Despite these advancements, there remain several obstacles preventing the successful application of these approaches in larger mammals such as dogs and humans. This review covers Nonviral Gene Therapy approaches using both in vivo Gene delivery and ex vivo Gene transfer. Plasmid-based approaches, as well as integrating transposons are examined for efficacy, risks and limitations. Results are presented on the only human clinical trial in hemophilia that utilized Nonviral approaches.
-
Sleeping Beauty Transposon-Mediated Nonviral Gene Therapy
BioDrugs, 2006Co-Authors: Stephen Fernando, Bradley S. FletcherAbstract:Safe and effective delivery of Genetic material to mammalian tissues would significantly expand the therapeutic possibilities for a large number of medical conditions. Unfortunately, the promise of Gene Therapy has been hampered by technical challenges, the induction of immune responses, and inadequate expression over time. Despite these setbacks, progress continues to be made and the anticipated benefits may come to fruition for certain disorders. In terms of delivery, Nonviral vector systems are particularly attractive as they are simple to produce, can be stored for long periods of time, and induce no specific immune responses. A significant drawback to Nonviral systems has been the lack of persistent expression, as plasmids are lost or degraded when delivered to living tissues. The recent application of integrating transposons to Nonviral Gene delivery has significantly helped to overcome this obstacle, because it allows for genomic integration and long-term expression. Recent advances in transposon-based vector systems hold promise as new technologies that may unlock the potential of Gene Therapy; however, technical and safety issues still need refinement.
Jong-sang Park - One of the best experts on this subject based on the ideXlab platform.
-
Nonviral Gene Therapy in vivo with PAM-RG4/apoptin as a potential brain tumor therapeutic
International journal of nanomedicine, 2013Co-Authors: Kihoon Nam, Sunghyun Choi, Cheng Z Bai, Yan Lee, Jong-sang ParkAbstract:Background Glioma is still one of the most complicated forms of brain tumor to remove completely due to its location and the lack of an efficient means to specifically eliminate tumor cells. For these reasons, this study has examined the effectiveness of a Nonviral Gene Therapy approach utilizing a tumor-selective killer Gene on a brain tumor xenograft model.
-
Nonviral Gene Therapy in vivo with pam rg4 apoptin as a potential brain tumor therapeutic
International Journal of Nanomedicine, 2013Co-Authors: Kihoon Nam, Sunghyun Choi, Cheng Z Bai, Yan Lee, Jong-sang ParkAbstract:Background Glioma is still one of the most complicated forms of brain tumor to remove completely due to its location and the lack of an efficient means to specifically eliminate tumor cells. For these reasons, this study has examined the effectiveness of a Nonviral Gene Therapy approach utilizing a tumor-selective killer Gene on a brain tumor xenograft model.
